INBX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 22.20%

Insider Buying (Last 12 Months): $10,896,731.13

Insider Selling (Last 12 Months): $10,290,000.00

Inhibrx Insider Trading History Chart

Inhibrx Share Price & Price History

^$14.17

▲ +0.11 (0.78%)

As of 06/28/2024 06:35 PM ET

Days: 30 | 90 | 365

AI's Next Magnificent Seven

From The Oxford Club | Ad

The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.

See His Breakdown of the Seven Stocks You Should Own Here.

Inhibrx Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/5/2024	Jon Faiz Kayyem	Director	Buy	57,549	$17.32	$996,748.68	1,150,410
5/28/2024	Brendan P. Eckelman	Insider	Sell	300,000	$34.30	$10,290,000.00	1,735,553
8/28/2023	Global Investors Lp Viking	Major Shareholder	Buy	511,627	$19.35	$9,899,982.45	511,627
2/1/2023	Brendan P. Eckelman	Insider	Sell	28,750	$24.73	$710,987.50	2,086,803
1/23/2023	Jon Faiz Kayyem	Director	Sell	9,500	$25.26	$239,970.00	3,224,301
1/23/2023	Mark Lappe	CEO	Sell	21,665	$25.36	$549,424.40	2,490,587
1/3/2023	Brendan P. Eckelman	Insider	Sell	32,895	$23.77	$781,914.15	2,122,658
12/21/2022	Jon Faiz Kayyem	Director	Sell	9,500	$27.02	$256,690.00	3,233,801
12/19/2022	Mark Lappe	CEO	Sell	26,000	$25.56	$664,560.00	2,512,252
12/6/2022	Brendan P. Eckelman	Insider	Sell	40,000	$27.22	$1,088,800.00	2,155,553
11/21/2022	Jon Faiz Kayyem	Director	Sell	9,500	$29.89	$283,955.00	3,243,301
11/1/2022	Brendan P. Eckelman	Insider	Sell	40,000	$33.51	$1,340,400.00	2,195,553
10/21/2022	Jon Faiz Kayyem	Director	Sell	9,500	$30.13	$286,235.00	3,252,801
10/17/2022	Mark Lappe	CEO	Sell	26,000	$29.59	$769,340.00	2,564,252
10/7/2022	Global Investors Lp Viking	Major Shareholder	Buy	1,333,333	$30.00	$39,999,990.00	2,427,307
10/4/2022	Brendan P. Eckelman	Insider	Sell	40,000	$27.82	$1,112,800.00	2,235,553
8/2/2022	Brendan P. Eckelman	Insider	Sell	24,500	$17.70	$433,650.00	2,491,053
7/7/2022	Brendan P. Eckelman	Insider	Sell	40,000	$17.17	$686,800.00	2,515,553
4/5/2022	Brendan P. Eckelman	Insider	Sell	400	$25.04	$10,016.00

Odds of Biden Replacement Up 105%!

From The Freeport Society | Ad

The media has now officially turned on him. But while Trump supporters are celebrating… The Democratic party is readying a Plan B that could change the face of America forever.

Click here for my urgent election update.

SEC Filings (Institutional Ownership Changes) for Inhibrx (NASDAQ:INBX)

82.46% of Inhibrx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inhibrx Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/17/2024	RA Capital Management L.P.	2,629,837	$91.94M	1.2%	-44.3%	5.019%
5/16/2024	California State Teachers Retirement System	22,593	$0.79M	0.0%	-2.4%	0.043%
5/16/2024	Black Maple Capital Management LP	15,863	$0.56M	0.3%	N/A	0.030%
5/15/2024	Price T Rowe Associates Inc. MD	14,812	$0.52M	0.0%	+8.1%	0.028%
5/15/2024	Alpine Global Management LLC	35,000	$1.22M	0.3%	N/A	0.067%
5/14/2024	Platinum Investment Management Ltd.	145,966	$5.10M	0.2%	-13.0%	0.279%
5/10/2024	Vanguard Group Inc.	1,861,469	$65.08M	0.0%	-0.7%	3.561%
5/10/2024	MMCAP International Inc. SPC	451,433	$15.78M	2.1%	N/A	0.863%
5/8/2024	Entropy Technologies LP	10,982	$0.38M	0.0%	N/A	0.021%
5/8/2024	ProShare Advisors LLC	16,741	$0.59M	0.0%	+92.2%	0.032%
5/8/2024	Russell Investments Group Ltd.	190,389	$6.66M	0.0%	-56.3%	0.364%
5/7/2024	Swiss National Bank	42,000	$1.47M	0.0%	+8.5%	0.080%
5/2/2024	FORA Capital LLC	16,103	$0.56M	0.0%	N/A	0.031%
5/2/2024	Fifth Lane Capital LP	10,200	$0.36M	0.3%	N/A	0.020%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	21,920	$0.77M	0.0%	+7.0%	0.042%
4/29/2024	China Universal Asset Management Co. Ltd.	9,106	$0.32M	0.0%	+66.4%	0.017%
4/17/2024	Hennion & Walsh Asset Management Inc.	30,561	$1.07M	0.1%	+2.5%	0.064%
3/5/2024	Wellington Management Group LLP	145,398	$5.53M	0.0%	-16.9%	0.307%
2/20/2024	Readystate Asset Management LP	13,839	$0.53M	0.0%	N/A	0.029%
2/15/2024	PFM Health Sciences LP	537,964	$20.44M	1.2%	+86.4%	1.138%
2/15/2024	Birchview Capital LP	48,448	$1.84M	1.5%	-31.2%	0.102%
2/14/2024	Bellevue Group AG	24,600	$0.94M	0.0%	-49.6%	0.052%
2/14/2024	Platinum Investment Management Ltd.	167,763	$6.38M	0.3%	-26.8%	0.355%
2/14/2024	Vestal Point Capital LP	1,530,000	$58.14M	6.2%	N/A	3.235%
2/13/2024	Capital Research Global Investors	712,360	$27.07M	0.0%	-41.7%	1.506%
2/13/2024	Rafferty Asset Management LLC	103,246	$3.92M	0.0%	-10.9%	0.218%
2/13/2024	Campbell & CO Investment Adviser LLC	23,516	$0.89M	0.1%	N/A	0.050%
2/9/2024	HCR Wealth Advisors	6,300	$0.24M	0.0%	N/A	0.013%
2/8/2024	Quadrant Capital Group LLC	690	$26K	0.0%	N/A	0.001%
2/7/2024	Principal Financial Group Inc.	10,368	$0.39M	0.0%	-3.7%	0.022%
2/7/2024	E Fund Management Co. Ltd.	5,512	$0.21M	0.0%	N/A	0.012%
2/6/2024	Charles Schwab Investment Management Inc.	229,866	$8.74M	0.0%	+8.4%	0.486%
2/6/2024	AJOVista LLC	678	$26K	0.0%	N/A	0.001%
2/6/2024	M&T Bank Corp	23,843	$0.91M	0.0%	-16.4%	0.050%
2/6/2024	Amalgamated Bank	4,250	$0.16M	0.0%	-7.6%	0.009%
2/6/2024	Swiss National Bank	38,700	$1.47M	0.0%	-32.8%	0.082%
2/5/2024	Russell Investments Group Ltd.	435,450	$16.55M	0.0%	-5.1%	0.921%
2/1/2024	Signaturefd LLC	758	$29K	0.0%	+4,637.5%	0.002%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	20,494	$0.78M	0.0%	+6.9%	0.043%
1/24/2024	Arizona State Retirement System	5,494	$0.21M	0.0%	N/A	0.012%
1/24/2024	China Universal Asset Management Co. Ltd.	5,471	$0.21M	0.0%	+389.8%	0.012%
1/5/2024	Exchange Traded Concepts LLC	6,705	$0.26M	0.0%	+34.0%	0.014%
12/18/2023	Vanguard Group Inc.	1,789,811	$32.84M	0.0%	+1.0%	3.785%
12/6/2023	Citigroup Inc.	49,244	$0.90M	0.0%	+3.4%	0.104%
12/1/2023	Wellington Management Group LLP	174,899	$3.21M	0.0%	+24.4%	0.370%
11/15/2023	RA Capital Management L.P.	4,724,207	$86.69M	1.7%	+22.6%	9.990%
11/14/2023	Eventide Asset Management LLC	434,026	$7.96M	0.1%	N/A	0.994%
11/14/2023	Profund Advisors LLC	19,746	$0.36M	0.0%	-18.3%	0.045%
11/13/2023	FMR LLC	1,517,595	$27.85M	0.0%	-14.3%	3.475%
11/13/2023	Rafferty Asset Management LLC	115,828	$2.13M	0.0%	-12.4%	0.265%
11/9/2023	Loomis Sayles & Co. L P	1,116,484	$20.49M	0.0%	-3.0%	2.557%
11/9/2023	Citigroup Inc.	49,244	$0.90M	0.0%	+3.4%	0.113%
11/8/2023	Charles Schwab Investment Management Inc.	212,104	$3.89M	0.0%	-13.8%	0.486%
11/8/2023	Swiss National Bank	57,600	$1.06M	0.0%	+2.1%	0.132%
11/7/2023	Barclays PLC	63,177	$1.15M	0.0%	-7.8%	0.145%
11/7/2023	Fox Run Management L.L.C.	12,621	$0.23M	0.1%	N/A	0.029%
10/27/2023	Hennion & Walsh Asset Management Inc.	27,731	$0.51M	0.0%	+89.5%	0.064%
10/26/2023	Mirae Asset Global Investments Co. Ltd.	19,163	$0.35M	0.0%	-3.8%	0.044%
10/24/2023	Bank of New York Mellon Corp	114,388	$2.10M	0.0%	-0.8%	0.262%
8/24/2023	Perceptive Advisors LLC	3,624,182	$94.08M	2.7%	+0.2%	8.299%
8/15/2023	Sphera Funds Management LTD.	50,000	$1.30M	0.2%	N/A	0.114%
8/14/2023	ArrowMark Colorado Holdings LLC	958,880	$24.89M	0.3%	+1.9%	2.196%
8/14/2023	Bellevue Group AG	48,800	$1.27M	0.0%	+64.3%	0.112%
8/11/2023	Natixis	45,000	$1.17M	0.0%	N/A	0.103%
8/11/2023	Velan Capital Investment Management LP	25,000	$0.65M	0.6%	N/A	0.057%
8/11/2023	Platinum Investment Management Ltd.	229,036	$5.95M	0.2%	+3.1%	0.524%
8/10/2023	Profund Advisors LLC	24,155	$0.63M	0.0%	-16.1%	0.055%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	19,918	$0.52M	0.0%	-6.7%	0.046%
8/10/2023	Russell Investments Group Ltd.	425,541	$11.05M	0.0%	+33.6%	0.976%
8/10/2023	Citigroup Inc.	47,633	$1.24M	0.0%	-61.7%	0.109%
8/9/2023	RS Crum Inc.	14,659	$0.38M	0.1%	N/A	0.034%
8/7/2023	Principal Financial Group Inc.	10,343	$0.27M	0.0%	N/A	0.024%
8/4/2023	American International Group Inc.	16,530	$0.43M	0.0%	+5.1%	0.038%
8/3/2023	Bank of New York Mellon Corp	115,296	$2.99M	0.0%	+9.4%	0.264%
7/20/2023	Exchange Traded Concepts LLC	5,165	$0.13M	0.0%	N/A	0.012%
5/12/2023	Profund Advisors LLC	28,799	$0.54M	0.0%	N/A	0.066%
5/12/2023	Platinum Investment Management Ltd.	222,209	$4.19M	0.1%	+38.8%	0.509%
5/11/2023	M&T Bank Corp	21,804	$0.41M	0.0%	+22.4%	0.050%
5/11/2023	Citigroup Inc.	124,335	$2.35M	0.0%	+43.7%	0.285%
5/9/2023	Tower Research Capital LLC TRC	6,348	$0.12M	0.0%	+28.6%	0.015%
5/9/2023	California State Teachers Retirement System	35,068	$0.66M	0.0%	+5.1%	0.080%
5/9/2023	Russell Investments Group Ltd.	318,505	$6.01M	0.0%	-0.3%	0.731%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	3,059	$58K	0.0%	-15.4%	0.007%
5/4/2023	Barclays PLC	64,661	$1.19M	0.0%	-39.3%	0.148%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	21,356	$0.40M	0.0%	+46.0%	0.049%
5/4/2023	Los Angeles Capital Management LLC	30,823	$0.58M	0.0%	-25.5%	0.071%
5/3/2023	Jump Financial LLC	25,509	$0.48M	0.0%	-23.0%	0.059%
5/2/2023	Amalgamated Bank	4,604	$87K	0.0%	-15.6%	0.011%
5/1/2023	Virtu Financial LLC	10,369	$0.20M	0.0%	N/A	0.024%
4/28/2023	SG Americas Securities LLC	15,163	$0.29M	0.0%	+249.5%	0.035%
3/23/2023	MetLife Investment Management LLC	17,746	$0.44M	0.0%	+3.0%	0.041%
2/15/2023	Endurant Capital Management LP	13,485	$0.33M	0.1%	N/A	0.031%
2/14/2023	RA Capital Management L.P.	3,853,867	$94.96M	1.9%	N/A	8.849%
2/14/2023	Pura Vida Investments LLC	93,575	$2.31M	0.1%	N/A	0.215%
2/13/2023	Platinum Investment Management Ltd.	160,127	$3.95M	0.2%	+9.5%	0.368%
2/13/2023	Gyon Technologies Capital Management LP	44,074	$1.09M	0.4%	N/A	0.101%
2/13/2023	GSA Capital Partners LLP	19,068	$0.47M	0.1%	N/A	0.044%
2/13/2023	M&T Bank Corp	28,965	$2.18M	0.0%	+7.0%	0.067%
2/10/2023	New York Life Investment Management LLC	25,458	$0.63M	0.0%	+12.7%	0.058%
2/10/2023	Schroder Investment Management Group	375,075	$9.24M	0.0%	-19.2%	0.861%

Data available starting January 2016

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Today's Range

Now: $14.17

$13.75

$14.78

50 Day Range

MA: $26.87

$14.06

$34.70

52 Week Range

Now: $14.17

$13.67

$18.95

Volume

823,828 shs

Average Volume

357,817 shs

Market Capitalization

$205.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Inhibrx?: Inhibrx's top insider shareholders include:
Jon Faiz Kayyem (Director)
Mark Lappe (CEO)
Brendan P Eckelman (Insider)
Global Investors Lp Viking (Major Shareholder)
Learn More about top insider investors at Inhibrx.
Who are the major institutional investors of Inhibrx?: Inhibrx's top institutional shareholders include:
RA Capital Management L.P. — 5.02%
Vanguard Group Inc. — 3.56%
MMCAP International Inc. SPC — 0.86%
Russell Investments Group Ltd. — 0.36%
Platinum Investment Management Ltd. — 0.28%
Swiss National Bank — 0.08%
Learn More about top institutional investors of Inhibrx stock.
Which major investors are selling Inhibrx stock?: Within the last quarter, INBX stock was sold by these institutional investors:
RA Capital Management L.P.
Russell Investments Group Ltd.
Platinum Investment Management Ltd.
Vanguard Group Inc.
California State Teachers Retirement System
Which major investors are buying Inhibrx stock?: During the last quarter, INBX stock was acquired by institutional investors including:
MMCAP International Inc. SPC
Alpine Global Management LLC
FORA Capital LLC
Equitec Proprietary Markets LLC
Black Maple Capital Management LP
Entropy Technologies LP
Fifth Lane Capital LP
ProShare Advisors LLC
During the previous year, these company insiders have bought Inhibrx stock:
Jon Faiz Kayyem (Director)
Mark Lappe (CEO)
Learn More investors buying Inhibrx stock.